Daniel Henaff is the R&D Manager at ID-Solutions. After completing his Ph.D. in 2010 at the Institute of Molecular Genetics of Montpellier, he did a post-doc at the University of Montreal and the Centre for Pathogens and Biotechnologies studies. Having worked on pathogen biology for several years, he is now in charge of the digital PCR and DNA isolation development in the oncology field at ID-Solutions.
Caroline Charky graduated from HEC Montreal with an MSc in management in Technological Entrepreneurship and has more than 15 years experience in life science startups in North America and Europe. Caroline joined Stilla in March 2016, where she serves as VP of commercial operations.
This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal™ Digital PCR with the Naica™ System from Stilla Technologies.
The speakers will discuss the detection of EGFR, BRAF, NRAS, and KRAS mutations as well as pediatric and adult cerebral tumor classification panels.
From this webinar participants can:
- Understand the liquid biopsy process for EGFR, BRAF, NRAS, and KRAS mutations;
- Learn about the benefits of the Crystal Digital PCR platform in combination with research-use-only kits;
- Hear why digital PCR is a particularly useful technique for the detection of mutations, therapeutic monitoring, and resistance appearance;
- Learn about the different steps of the liquid biopsy workflow, from DNA isolation to DNA quantification and qualification and DNA genotyping, with dPCR multiplex kits